ANIX Stock Analysis: Buy, Sell, or Hold?
ANIX - Anixa Biosciences, Inc.
$2.58
0.08 (3.20%)
▲
5d:
-0.39%
30d:
-12.84%
90d:
-18.87%
BUY
MODERATE Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: Mar 13, 2026
0d
Smart Money Accumulation
ANIX is down 5.7% this week, but smart money is accumulating calls. Top strike: $2.5 2026-04-17 with 149 OI. Call ratio: 100% View Scanner →
Strength: 7.8/10
Get Alerted When ANIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ANIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ANIX is currently trading at $2.58, which is considered oversold relative to its 30-day fair value range of $2.66 to $2.98.
Technical Outlook: Technically, ANIX is in a strong downtrend. Immediate support is located at $2.44, while resistance sits at $2.90. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: ANIX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.75 (+316.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANIX is in a strong downtrend. Immediate support is located at $2.44, while resistance sits at $2.90. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: ANIX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.75 (+316.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.66 -
$2.98
Company Quality Score
50/100
(HOLD)
Options IV Signal
56th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 56th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 316.7% below Wall St target ($10.75)
Fair Price Analysis
30-Day Fair Range
$2.66 -
$2.98
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.60
(23.2%)
Support & Resistance Levels
Support Level
$2.44
Resistance Level
$2.90
Current Trend
Strong Downtrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.97
Wall Street Target
$10.75
(+316.7%)
Share & Embed Analysis
Last updated: March 31, 2026 5:59 PM ET
Data refreshes hourly during market hours. Next update: 6:59 PM
Data refreshes hourly during market hours. Next update: 6:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Arnold M Baskies
BUY
10000 shares
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 60 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$138 | 57 HOLD |
